Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics 7: Identification of Drug Resistance Mechanisms

Gene copy number alterations and differential gene expression in the acquired resistance of ovarian cancer cells to taxanes

Dejan Juric, Yan C. Wang, Ron X. Yu, George E. Duran, E. Brian Francisco and Branimir I. Sikic
Dejan Juric
Stanford University School of Medicine, Stanford, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan C. Wang
Stanford University School of Medicine, Stanford, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ron X. Yu
Stanford University School of Medicine, Stanford, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George E. Duran
Stanford University School of Medicine, Stanford, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Brian Francisco
Stanford University School of Medicine, Stanford, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Branimir I. Sikic
Stanford University School of Medicine, Stanford, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2006
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 47, 2006

Abstract

1252

Ovarian cancer is the most common cause of death among women with gynecologic malignancies. Close to 75% of the patients have advanced-stage disease at diagnosis and are often characterized by rapid development of resistance to chemotherapy. In order to understand biological mechanisms underlying this behavior, we have developed a set of taxane-resistance models consisting of six parental ovarian cancer cell lines (A2780/1A9, ES-2, MES-OV, OVCA429, OVCA433 and OVCAR3) and 24 resistant variants exhibiting at least 10-fold resistance to either paclitaxel or docetaxel, selected with or without PSC, a modulator of P-glycoprotein. We hypothesized that the drug resistance phenotype depends on multiple changes in the transcriptional programs of resistant variants and the accumulation of numerous chromosomal alterations conferring selective advantages under drug pressure. High-resolution gene copy number and gene expression profiling were performed using a 42,000-element cDNA microarray platform. Parallel measures of gene copy number variation and gene expression were obtained for a total of 12,480 unique UniGene clusters. Gene copy number profiles were first transformed into regions of consistent gene copy number level using a recently developed circular binary segmentation algorithm (CBS) and deemed changed based on the reference distribution of multiple self-to-self hybridizations. The profiled cell lines exhibited numerous complex gene copy number aberrations, which is consistent with a high degree of aneuploidy in these tumors. The most common alterations include 1q, 3q, 8q, 17q and 20q. The global impact of gene copy number alterations on gene expression was first estimated using a linear regression model which indicated that at least 10% of all variation in gene expression among the analyzed cell lines is directly attributable to underlying variation in gene copy number. Since this relationship is likely to be much larger for a selected number of genes with higher biological importance, gene copy number and gene expression data were also integrated on a gene-by-gene level using signal-to-noise computation coupled with permutation testing. Gene expression profiles of 1,266 clones were found to be significantly associated with gene copy number alterations (q<0.05). These genes were then correlated with the taxane resistance phenotype using Significance Analysis of Microarrays (SAM), and 36 and 38 clones were found to be associated with P-gp and non-P-gp mediated drug resistance phenotypes, respectively (q<0.05). Finally, molecular interactions and potential functional relevance of identified genes were investigated using pathway analysis tools. Collectively, these observations provide a framework for future studies on the roles of genome instability and the accumulated genetic alterations in the development of chemoresistance.

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 66 (8 Supplement)
April 2006
Volume 66, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Gene copy number alterations and differential gene expression in the acquired resistance of ovarian cancer cells to taxanes
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Gene copy number alterations and differential gene expression in the acquired resistance of ovarian cancer cells to taxanes
Dejan Juric, Yan C. Wang, Ron X. Yu, George E. Duran, E. Brian Francisco and Branimir I. Sikic
Cancer Res April 15 2006 (66) (8 Supplement) 296;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Gene copy number alterations and differential gene expression in the acquired resistance of ovarian cancer cells to taxanes
Dejan Juric, Yan C. Wang, Ron X. Yu, George E. Duran, E. Brian Francisco and Branimir I. Sikic
Cancer Res April 15 2006 (66) (8 Supplement) 296;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Establishment and characterization of paclitaxel-resistant prostate cancer cell lines
  • Insulin-like growth factor receptor signaling pathways and resistance to farnesyl transferase inhibitor SCH66336 (Lonafarnib) in head and neck squamous cell carcinoma
  • 2-Methoxyestradiol-resistant cancer cells overexpress functional laminin α4
Show more Experimental and Molecular Therapeutics 7: Identification of Drug Resistance Mechanisms
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement